TSPO and glioblastoma: In line with this, other TSPO-targeting radioligands, DPA-714 and DPA-713, have been designed, which also allowed for labeling with 18F. Clinical research showed that [18F]-DPA-714 can provide information on the degree of immunosuppression in the TME in a glioblastoma mouse model, and it was concluded that imaging can assist in monitoring chemotherapy treatment outcomes [119, 123].